Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATF4 | P18848 | 8/20 | 0.51 |
| ▸ | ACACB | O00763 | 9/20 | 0.49 |
| ▸ | ACACA | Q13085 | 7/20 | 0.49 |
| ▸ | CKS1B | P61024 | 1/20 | 0.43 |
| ▸ | SKP1 | P63208 | 1/20 | 0.43 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.43 |
| ▸ | DRD2 | P14416 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21882080 | 0.86 | ATF4 (0.59) | ATF4CKS1BSKP1SKP2 | |
| SCHEMBL29436919 | 0.86 | ATF4 (0.59) | ATF4CKS1BSKP1SKP2 | |
| SCHEMBL22777576 | 0.86 | ATF4 (0.56) | ATF4 | |
| SCHEMBL29526791 | 0.85 | ACACB (0.52) | ATF4ACACBACACA | |
| SCHEMBL23920476 | 0.85 | ACACB (0.52) | ATF4ACACBACACA | |
| SCHEMBL28720394 | 0.85 | ACACB (0.52) | ATF4ACACBACACA | |
| SCHEMBL22373842 | 0.84 | ENPP2 (0.47) | ACACBACACACKS1BSKP1SKP2 | |
| SCHEMBL22777603 | 0.83 | KDM4E (0.57) | ACACBACACA | |
| SCHEMBL23920292 | 0.81 | ATF4 (0.51) | ATF4ACACBACACACKS1BSKP1 | |
| SCHEMBL23920505 | 0.80 | ATF4 (0.56) | ATF4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3983378-A1 | INHIBITORS OF INTEGRATED STRESS RESPONSE PATHWAY | Praxis Biotech LLC (US) | 2022-04-20 | — | — | EP | disclosed |
| CN-114206829-A | Integrated stress response pathway inhibitors | 普拉西斯生物技术有限责任公司 | 2022-03-18 | — | — | CN | disclosed |
| US-20210317102-A1 | INHIBITORS OF INTEGRATED STRESS RESPONSE PATHWAY | ALTOS LABS, INC. | 2021-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210317102-A1 | INHIBITORS OF INTEGRATED STRESS RESPONSE PATHWAY | ATF4, DDIT3, ATF1 | ATF4 1/4885ACACB 862/4885ACACA 1961/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.